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Abstract
Background: Interactions of inflammatory cells with pancreatic cancer cells play crucial roles in pancreatic cancer,
however the dynamic changes of inflammatory cell populations in pancreatic cancerogensis and after chemotherapy
have not been well eclucidated. The combinational use of aspirin and atrovastatin (Lipitor) have been widely
prescribled for cardio-cerebral vascular diseases mainly by regulation of inflammations, and they have been also
reported to have plausible anti-tumor effects, however their potential roles in pancreatic cancerogenesis and
chemotherapeutic effects have been seldom investigated. We scanned the dynamic changes of pan-inflammatory cell
populations in pancreatic cancerogensis and after chemotherapy and found the potential target cell populations. Then
we tested the roles of aspirin and Lipitor to regulate these inflammatory cell populations and their effects on pancreatic
cancerogenesis and chemotherapeutic effects.
Methods: Cancerogen, dimethylbenzanthracene (DMBA), was used to induce pancreatic cancerogenesis and
subcatunous implantation of syngenic murine Panc02 pancreatic cancer cells was adopted as well. Gemcitabine was used
for chemotherapy. The peripheral blood, pancreatic lesions and tumor samples were harvested and analyzed to search for
the potential target cell populations. The roles of aspirin and Lipitor to regulate these cell populations and their potential
effects on pancreatic cancerogenesis and chemotherapeutic efficacy were investigated both in vitro and in vivo.
Results: We found progressive accumulations of myeloid-derived suppressor cells (MDSC) and M2-polarzied tumor
associated macrophages(M2) in pancreatic lesions accompanied with dynamic reducations of cytotoxic T cells(CTL) and
helper T cells(Th) in the progression of pancreatic cancerogenesis. After gemcitabine treatment, the MDSC significantly
reduced, however M2 soared up unexpectedly. Aspirin could significantly inhibit the MDSC and M2 to prevent pancreatic
cancerogenesis and improve chemotherapeutic effects of gemcitabine, however Lipitor did not significantly affect MDSC,
instead it could promote M2 to attenuate the postive effects of aspirin and gemcitabine.
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Conclusions: MDSC and M2 accumulate in progression of pancreatic cancerogenesis and gemcitabine can induce M2.
Aspirin could prevent pancreatic cancerogenesis and improve efficacy of gemcitabine partially by inhibiting MDSC and
M2, however when used in combination, Lipitor could weaken the efficacy of aspirin and gemcitabine partially by
promoting M2.
Keywords: Pancreatic cancer, Cancerogenesis, Chemotherapy, Gemcitabine, Aspirin, Atorvastatin, Myeloid derived
suppressor cells, Tumor associated macrophages
Background
Pancreatic cancer is a devastating disease with a rising
incidence, rendering it the fourth most common cause
of cancer-related mortality [1]. Pancreatic cancer pro-
ceeds through a morphological spectrum of tumor pre-
cursor lesions, named pancreatic intradutal neoplasia
(PanIN), which makes PanINs as potential targets for
the prevention of pancreatic cancer [2]. Chemotherapy
is the main treatment for unresectable pancreatic cancer
patients. Gemcitabine is used as a first-line drug, how-
ever, the objective response rate to gemcitabine is ap-
proximately 10–20 % and the secendary drug resistance
is high up to 80 % [3]. The pathological traits of pancre-
atic cancer are exclusive with highly dense fibrosis and
abundant infiltration of inflammatory cells which have
been reported to affect pancreatic cancerogenesis and
the chemotherapeutic effects of gemcitabine [4]. Al-
though myeloid derived suppressor cells (MDSC) [5],
tumor associated macrophages (TAM) [6] and dendritic
cells (DC) [7] have been reported to affect the biological
behaviors of pancreatic cells and the efficacy of chemo-
therapy and immunochemotherapy, the dynamic changes
of pan-inflammatory cell populations in the process of
pancreatic cancerogenesis and after chemotherapy are
little known. So systematic scanning of the dynamic
changes of pan-inflammatory cell populations in the
process of pancreatic cancerogenesis and after chemo-
therapy can provide important information for further
understanding the interactions of inflammatory cells
with pancreatic cancer and chemotherapy which can be
of great value to prevent pancreatic cancer and improve
the chemotherapeutic efficacy.
Aspirin has strong effects to inhibit inflammations and
it have been also reproted to inhibit the immunosup-
pressive MDSC [8]. Atorvastatin (Lipitor), one of the
statins, always prescribled with aspirin to prevent and
treat cardo-cerebral vascular disease by lowering down
sera lipid and it was also reported that Lipitor could in-
hibit the activation of macropahges [9, 10]. Recent years,
these two drugs have been reported to have plausible
anti-tumor effects, however the results were conflicting
[11–13], and their effects on pancreatic cancerogenesis
and chemotherapy were seldom investigated. Consider-
ing the potential roles of these two drugs in regulation
of cancer related inflammations, we initially hypothe-
sized that aspirin and Lipitor could probably have pre-
ventive roles for pancreatic cancer and improve the
chemotherapeutic efficacy of gemcitabine.
Herein, after scanning 11 inflammatory cell popula-
tions in the process of pancreatic cancerogenesis and
after chemotherapy, we found MDSC and M2-polarized
TAM(M2) changed most significantly which could prob-
ably be powerful targets for prevention of pancreatic
cancerogenesis and improving chemotherapeutic effi-
cacy. Consquently, aspirin could inhibit the expansion of
MDSC and M2, however, Lipitor promted M2. Aspirin
substantially prevented the pancreatic cancerogenesis
and improved chemotherapeutic effects of gemcitabine
partially by inhibiting MDSC and M2, however Lipitor




Male 4-week-old or 8-week-old C57BL/6J mice were
purchased from VITAL RIVER Animal Center (Beijing,
China). All of the animals were maintained in a
pathogen-free animal facility for at least 1 week prior to
use. Animal studies were performed in accordance with
the institutional guidelines of Peking Union Medical
College Hospital and were approved by the Lab Animal
Committee of Peking Union Medical College Hospital.
Reagents and antibodies
Gemcitabine was purchased from Eli Lilly (Indiana,
USA). Granulocyte–macrophage colony-stimulating fac-
tor (GM-CSF) were purchased from BD Biosciences
(New Jersey, USA). Aspirin, atorvastatine (Lipitor),
carboxyfluorescein succinimidyl amino ester (CFSE),
dimethylbenzanthracene (DMBA) and dimethyl sulfox-
ide (DMSO) were purchased from Sigma-Aldrich (St.
Louis, USA). CV-7 PTFe suture lines were purchased
from GORE-TEX Suture (W.L. Gore & Associates, Inc,
Arizona, USA). The antibodies were purchased from BD
Biosciences (New Jersey, USA)., Biolegend (San Diego,
USA) or Santa Cruz Biotechnology (Texas, USA). All of
the antibodies used in this study were listed in the
(Additional file 1: Table S1).
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Cell lines and bone marrow cells
The murine Panc02 pancreatic cancer cell line is a
sarcoma-like adenocarcinoma cell line that was derived
from a 3-methylcholanthrene-induced tumor in a
C57BL/6J female mouse. The murine monocyte cell line
RAW 264.7 was purchased from Cell Line Center of
Chinese Academy of Medicine Sciences. These two cell
lines were maintained in high glucose DMEM (Dulbec-
co’s modified Eagle medium; Gibco BRL Co. Ltd., USA)
supplemented with 10 % FCS (fetal calf serum; Gibco
BRL Co. Ltd., USA) and 1 % penicillin and strepto-
mycin. Bone marrow cells (BMCs) from the femurs of
4-week-old C57BL/6J mice were prepared as previously
described [14]. When preparing BMCs, the T and B
lymphocytes in bone marrow were removed using CD3−T
cell and CD19−B cell positive selected magnetic beads
(MACS, MiltenyiBiotec., BergischGladbach, Germany) ac-
cording to the manufacturer’s protocols.
Flow cytometery
The peripheral blood was lysed using a red blood cell lys-
ing buffer according to the manufacturer’s protocols (Red
Blood Cell Lysing Buffer Hybri-Max™; Sigma-Aldrich,
USA). The subcutaneous tumor samples or the pancaretic
lesions were harvested by blunt dissection. These tissue
samples were cut into small pieces and minced using scal-
pel blades. Then, the minced pieces were mixed with 200
U/mL collagenase IV (Sigma-Aldrich, USA) and incubated
at 37 °C for 1.5 h for enzymatic dissociation. At the end of
the incubation, the cells were filtered through a 70-μm fil-
ter. The single cell suspension was collected in ice-cold
phosphate buffered saline (PBS) and incubated with the
antibodies in the darkroom for 30 min. Next, the stained
cells were resuspended in PBS with 1 % paraformaldehyde
and stored at 4 °C prior to flow cytometric analysis
(Accuri C6, BD, USA). For each analysis, an isotype-
matched monoclonal antibody was used as a negative
control. The total inflammatory cells (CD45+), total T
lymphocytes (CD3+), T helper cells (Th) (CD3+ CD4+),
cytotoxic T lymphocytes (CTL) (CD3+ CD8+), B lympho-
cytes (CD19+), granulocytes (Gr-1+), dendritic cells
(CD11c+), NK cells (NKP46+), NKT cells (CD3+NK1.1 +),
monocytes & macrophages (F4/80+), M1-polarized tumor
associated macrophages (TAM) (F4/80+CD16/32+CD206−),
M2-polarized TAM (F4/80+CD16/32+CD206+) and mye-
loid derived suppressor cells (MDSC) (CD11b+Gr-1+) were
detected. Each experiment was carried out in triplicates.
Hematoxylin-eosin staining
The tumor tissue and pancreatic lesion samples were fixed
in 10 % phosphate-buffered polyformalin and embedded
in paraffin. The formalin-fixed and paraffin-embedded
samples were cut into 4-μm thick sections, mounted on
poly-L-lysine–coated slides (Sigma-Aldrich, St. Louis,
MO), and dried over night at 37 °C. The sections were
then dewaxed in xylene and rehydrated according to the
standard histopathological procedures and stained with
hematoxylin and eosin.
Real time reverse transcribed polymerase chain reaction
(Real time RT-PCR)
The sorted cells, spleens and the tissues (fresh or frozen)
without obvious necrosis was homogenized and lysed
with Trizol reagent (Life Technologies, USA), and the
total RNA was extracted using an RNeasy kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
protocol. The total RNA was reverse transcribed into
cDNA using a high capacity RNA-to-cDNA kit (Life
technologies, USA). All the PCR reactions were carried
out on a Bio-Rad CFX96 PCR System (USA). The first
step was performed at 95 °C for 10 min, and the mRNA
expression levels were determined over 35–40 cycles
with 15 s of denaturation at 95 °C and annealing-
extension-data acquisition at 52–60 °C for 60 s using a
Power SYBR®Green PCR kit (UltraSYBR Mixture, KAPA
SYBR® FAST qPCR Kits). All the primer sequences are
listed in the (Additional file 1: Table S2). The relative
fold mRNA expression levels were determined using the
comparative Ct (ΔΔCt) method. All the reactions were
carried out in triplicates.
Elisa test
The sorted cells, spleen, and the fresh or frozen tumor tis-
sues were harvasted and lysed for elisa test. All of the
commercial sandwich ELISA kits used for the quantitation
of IL-2, IL-4, IL-6, IL-10, IL-12, IFN-γ, TNF-α and TGF-β
were purchased from R&D systems Inc.. The OD value of
each of the samples was measured at 450 nm using a
SpectraMax190 ELISA plate reader. Cytokine levels were
quantified from three titrations using standard curves and
expressed in pg/ml.
Western blotting
Cultured cell samples were immersed in protein extrac-
tion buffer and centrifuged. The supernatant was re-
moved and the protein concentration was measured
using the BCA method (Pierce, MO, USA). Twenty mi-
crograms of total protein was prepared for electrophor-
esis through an 8 % (v/v) sodiumdodecyl sulfate/
polyacrylamide gel and transferred to a polyvinyli-
denefluoride (PVDF) membrane. After incubation in 5 %
(w/v) nonfat dry milk for 0.5 h at room temperature to
block non-specific binding, the PVDF membrane was in-
cubated with primary antibodies overnight with agitation
at 4 °C. The membrane was then washed three times for
5 min each in TBST and incubated with HRP-
conjugated secondary antibodies (1:2000; Golden Bridge
Biological Technology, Beijing, China) in 5 % (w/v)
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nonfat dry milk and TBST for 30 min at room
temperature with agitation. After washing three times in
TBST, the bands were visualized with an Enhanced
Chemiluminescence system (Millipore, Billerica, USA).
The arginase-1 and CD206 antibodies (Santa Cruz,
USA) were used, respectively.
Myeloid dervied suppressor cells (MDSC) and tumor
asssociated macrophages (TAM) indcued by pancreatic
cancer in vitro
The tumor supernatant from Panc02 cells were collected
when 90 % of the confluence of Panc02 cells was
achieved in culture dish. The conditional medium was
perpared by mixing 80 % of the high glucose DMEM
containing 12.5 % FCS with 20 % of the tumor super-
natant. The conditional medium was used to induce
MDSC and TAM in vitro. To induce MDSC and M2,
10 ng/ml of GM-CSF was added into the conditional
medium as well. The cells were harvested 72 h later. For
analyzing the roles of different drugs, 18 h after incuba-
tion, the cells were divided into 4 groups, respectively:
the control group, the aspirin group (ASP, 5 mmol/l),
the Lipitor group (LIP, 40 μmol/l), and the aspirin + Lipi-
tor group (ASP + LIP, aspirin 5 mmol/l, Lipitor,
40 μmol/l). The aspirin was first dissolved in dimethyl
sulfoxide (DMSO) and then added to DMEM, with a
final DMSO concentration of less than 1 %. The cells
were harvested 72 h.
Murine pancreatic cancerogenesis model
To establish the spontaneous pancreatic cancerogenesis
model, the DMBA implantation in the distal pancreas
method was applied. Briefly, the mice were submitted to
pre-operative fasting for 6 h. The mice were anesthetized
with a chloral hydrate solution i.p injection (10 %, 20 μl/
10 g). A median laparotomy was performed; the incision
was approximately 1 cm long, and the distal pancreas
and spleen were gently removed from the abdominal
cavity. A purse-string suture of 10 mm in diameter was
performed using 7–0 CV-7 PTFe thread (GORE-TEX
Suture, USA). The DMBA crystals (1 mg/25 g; Sigma-
Aldrich, USA) were implanted in the distal pancreas.
The implantation site was carefully checked to ensure
there was no spillage of DMBA. The sutured pancreas
and spleen were gently returned to the abdominal cavity.
The incision was closed with 4–0 prolene suture lines.
This procedure is illustrated in the (Additional file 1:
Figure S1). The animals were subdivided into four
groups: the control group (Con.), the aspirin group
(ASP), the Lipitor group (LIP), and the combination of
aspirin and Lipitor group (ASP + LIP). The mice were
fed the appropriate drugs 2 weeks prior to surgery: water
for the control group; 20 mg/kg aspirin daily for the as-
pirin group; 10 mg/kg Lipitor daily for the Lipitor group;
and 20 mg/kg aspirin plus 10 mg/kg Lipitor daily for the
combinational group. After the surgery, the same drug
patterns were continued, and the drug dosages fed to
the mice were equivalent to those used to prevent car-
diovascular diseases and treat hyperlipemia clinically.
Two months after surgery, the mice were sacrificed and
the peripheral blood and pancreatic lesions were ana-
lyzed. Histological analysis for the pancreatic lesions was
performed by two pathologists back-to-back.
Carboxyfluorescein succinimidyl amino ester (CFSE)
staining of Panc02 cells
CFSE was used to monitor proliferation of Panc02 cells
in vitro. Breifly, the Panc02 cell suspension was diluted
into 107/ml and then the CFES/DMSO solution was
added. The final working solution of CFSE is 2.5 μmol/l.
30 min (at the room temperature) later, DMEM medium
with 10 % FCS was added to stop the reaction. And then
wash three times with PBS. The stained Panc02 cells
showed bright green under fluorescence microscope.
The stained Panc02 cells were co-cultured with BMCs
or RAW 264.7 in vitro for the further experiments.
Chemotherapy in vivtro
For in vitro experiments of gemcitabine treatment, the
Panc02 cells were incubated in high glucose DMEM
with BMCs or RAW 274.7 supplemented with 10 % FCS
and 1 % penicillin and streptomycin in the presence of
10 ng/ml of GM-CSF. The BMCs or RAW 264.7 were
co-cultured with Panc02 at a 10 × 105: 5 × 105 ratio in 6-
well-plates. Eighteen hours after incubation, the co-
cultured cells were divided into 5 groups: the co-culture
control group, the chemotherapy group (Chemo., gemci-
tabine, 20 μmol/l), the chemotherapy + aspirin group
(Chemo. + ASP, gemcitabine, 20 μmol/l; aspirin 5 mmol/
l), the chemotherapy + Lipitor group (Chemo. + LIP,
gemcitabine, 20 μmol/l; Lipitor, 40 μmol/l), and the
chemotherapy + aspirin + Lipitor group (Chemo. + ASP +
LIP, gemcitabine, 20 μmol/l; aspirin 5 mmol/l; Lipitor,
40 μmol/l). The co-cultured cells were harvested 72 h
after the drug treatment. Before harvesting, the prolifation
of Panc02 cells were evaluated under fluoresence micro-
scope. And then the co-cultured cells were prepared for
FCM analysis (Accuri C6, BD, USA). The inflammatory
cells in the co-culture were labeled as the CD45+ popula-
tions, and then the subpopulation in the CD45+ popula-
tion were sorted and analyzed.
Chemotherapy in vivo
To observe the effects of the combinational use of as-
pirin and Lipitor on the chemotherapy of pancreatic
cancer in vivo, the Panc02 cell s.c implantation model
was adopted. To establish the tumor bearing mouse
model, 2 × 106 Panc02 cells were subcutaneously
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implanted, which was previously determined to produce
tumor masses that would reach 100–250 mm3 in 2 weeks
after implantation. The mice were divided into five
groups: the control group (Con.), the chemotherapy
group (Chemo.), the chemotherapy + aspirin group
(Chemo. + ASP), the chemotherapy + Lipitor group
(Chemo. + LIP) and the chemotherapy + aspirin + Lipitor
group (Chemo. + ASP + LIP). Two weeks prior to cell
implantation, the mice were fed aspirin or Lipitor. Two
weeks after cell implantation, the chemotherapy drug
gemcitabine was administered 100 mg/kg intraperitoneal
(i.p) injection once a week. The tumor volume was mea-
sured every 3 days using calipers. Twenty-four days after
commencing chemotherapy, the tumor bearing mice
were sacrificed and the peripheral blood and tumor tis-
sue were analyzed.
Statistics
All data were presented as the Mean ± SEM. The
ANOVA, SNK-q test, paired student’s t-test and Fisher
exact test were applied appropriately, and a 95 % confi-
dence limit was considered to be significant, defined as
P < 0.05. The IBM SPSS Statistics software 22.0 version
and the Graphpad prism software 5.0 version were used
for statistical analysis and drawing the graphs (Version
5.0, Graph-Pad Software, La Jolla, CA, USA).
Results
The dynamic changs of inflammatory cells in peripheral
blood and pancreatic lesions in the process of pancreatic
cancerogenesis
Forty mice were used to establish the model of pancre-
atic cancerogenesis. Two months later, 8 mice died,
among the survivors, 6 cases were chronic pancreatitis
(CP), 5 cases were PanIN-1, 5 cases were PanIN-2, 7
cases were PanIN-3 and 9 cases were pancreatic cancer
(PC) (Fig. 1). The total number of CD45+ inflammatory
cells and the 11 subpopulations in peripheral blood and
pancreatic lesions were analyzed by FCM. In peripheral
blood, the total number of CD45+ inflammatory cells grad-
ually increased during the process of pancreatic cancero-
genesis. In peripheral blood, the total number of CD45+
inflammatory cells in PC was 12257.25 ± 4752.13/μl, com-
pared to 8874.67 ± 3456.32/μl in PanIN-3, 6443.29 ±
2356.44/μl in PanIN-2, 5421.24 ± 2006.71/μl in PanIN-1,
5041.77 ± 2118.32/μl in CP and 4475.54 ± 1456.99/μl in
control, respectively (PC: control, PC: CP, P < 0.01; PC:
PanIN-1, PC: PanIN-2, P < 0.05; PanIN-3: control, PanIN-
3:CP, PanIN-3: PanIN-1, P < 0.05; PanIN-2: control, P <
0.05). Then the propotions of subpopulations in CD45+
inflammatory cells were analyzed. The percentage of gran-
ulocyte in PC ((45.2 ± 5.76 %) was significantly higher than
that of control ((30.25 ± 5.76 %), CP ((31.40 ± 5.77 %),
PanIN-1 ((35.55 ± 6.78 %), PanIN-2 ((35.12 ± 7.66 %)
Fig. 1 The representative pictures of DMBA-induced pancreatic cancerogenesis process from chronic pancreatitis (CP) to PanIN (pancreatic intradutal
neoplasia) and invasive pancreatic cancer. a Normal pancreas, H&E, ×40; b chronic pancreatitis: the acinar atrophy and stroma hyperplasia, H&E, ×40.
c. PanIN-1: the columnar cells with a papillary intraductal arrangements, H&E, ×100. d PanIN-2: the papillary pseudostratified and hyper chromatic
lesions, H&E, ×100; e PanIN-3: the severe cellular atypia and cribriform architecture, H&E, ×100; f Invasive pancreatic cancer: the spare pancreatic cancer
cells in the stroma, H&E, ×200. (Blue arrows indicate representative lesions)
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(P < 0.05). As well, the percentage of MDSC in PC
((7.23 ± 1.53 %) was significantly higher than that of
control ((1.25 ± 1.06 %), CP ((2.10 ± 1.57 %), PanIN-1
((2.05 ± 1.78 %), PanIN-2 ((2.12 ± 1.06)%) and PanIN-3
((5.12 ± 1.66)%) (PC: control, PC: CP, PC: PanIN-1,
PC: PanIN-2, P < 0.01; PC: PanIN-3, P < 0.05; PanIN-
3: PanIN-2, PanIN-3: PanIN-1; PanIN-3:CP, PanIN-3:
control, P < 0.05), but the other inflammatory cell
populations were not significantly different. Compared
to the dynamic changes in peripheral blood, the
dynamic changes in pancreatic lesions were more
complicated, briely, the total number of CD45+ in-
flammatory cells and most of the subpopulations
increased significantly with the development of pan-
creatic ccancerogensis. After analyzing the propotions
of subpopulations in CD45+ inflammatory cells, the
percentages of granulocyte, MDSC, macrophage, and
M2 were significantly elevated with the progression of
pancreatic cancerogenesis, in contrary, the percent-
ages of helper T cell and cytotoxic T cell were signifi-
cantly decreased. The detail was summarized in
Table 1.
Table 1 The dynamic changes of the inflammatory cell populations in pancreatic lesions during pancreatic cancerogenesis
(%, Mean ± SEM)
Cell population Pancreatic lesions
Control (n = 6) CP (n = 6) PanIN-1 (n = 5) PanIN-2 (n = 5) PanIN-3 (n = 7) PC (n = 9)
Inflammatory cells 15.50 ± 3.45 27.04 ± 4.75* 30.53 ± 5.57* 34.53 ± 5.45* 45.23 ± 5.40**#& 49.54 ± 6.91**#&@
Th
15.13 ± 3.34 15.02 ± 3.47 11.02 ± 3.46 10.44 ± 2.30 8.03 ± 2.40*# 8.67 ± 3.11*#
2.15 ± 0.57 4.24 ± 0.94* 3.45 ± 1.01* 3.62 ± 0.54* 3.75 ± 2.40* 4.12 ± 0.93*
CTL 12.05 ± 3.55 12.51 ± 3.74 10.12 ± 2.13 7.11 ± 3.40 7.05 ± 2.05*# 6.04 ± 2.55*#
1.74 ± 0.25 3.21 ± 0.78* 3.23 ± 1.01* 2.87 ± 0.48* 3.3 ± 1.00* 3.04 ± 0.68*
B cell
15.07 ± 3.52 16.40 ± 4.22 15.28 ± 3.00 16.24 ± 3.02 14.00 ± 3.25 11.34 ± 3.26
2.12 ± 0.26 4.37 ± 1.01* 4.55 ± 0.87* 5.44 ± 0.75* 6.30 ± 1.24* 5.39 ± 1.27*
Granulocyte 35.56 ± 7.22 37.04 ± 5.78 40.52 ± 7.53 47.55 ± 5.07* 55.24 ± 7.30*# 60.24 ± 8.67**##
5.27 ± 1.26 10.51 ± 2.33* 13.11 ± 2.46* 15.78 ± 3.61** 25.78 ± 3.89**#&@ 31.12 ± 4.97**##&@
Mφ 12.22 ± 3.45 11.55 ± 3.22 14.28 ± 2.77 17.12 ± 4.54# 20.05 ± 4.43*# 22.15 ± 3.65*#
1.58 ± 0.42 3.24 ± 0.60* 3.51 ± 0.89* 5.91 ± 1.10**# 9.18 ± 2.16**##&&@ 12.11 ± 2.47**##&&@
DC
7.24 ± 2.25 8.46 ± 3.70 6.74 ± 4.22 10.86 ± 3.36 12.25 ± 4.57 11.23 ± 3.45
0.97 ± 0.47 2.15 ± 0.45* 2.04 ± 0.47* 3.56 ± 1.01* 5.52 ± 1.46**#& 5.31 ± 1.89**#&
NK 6.10 ± 1.22 5.84 ± 2.33 5.42 ± 1.65 6.24 ± 2.94 5.54 ± 1.93 4.22 ± 1.58
0.88 ± 0.24 1.68 ± 0.67* 1.98 ± 0.49* 2.27 ± 0.75* 2.51 ± 0.68* 2.29 ± 0.84*
NKT 3.01 ± 0.55 3.12 ± 0.97 2.01 ± 0.18 2.02 ± 0.65 2.76 ± 1.15 2.84 ± 1.44
0.44 ± 0.21 0.91 ± 0.31 0.67 ± 0.12 0.75 ± 0.09 0.91 ± 0.21 0.83 ± 0.08
MDSC
5.24 ± 2.16 7.25 ± 2.55 9.25 ± 3.42* 14.14 ± 2.75**# 15.25 ± 3.55**#& 22.34 ± 4.22**##&&@$
0.75 ± 0.15 1.79 ± 0.27* 2.75 ± 0.55* 3.64 ± 0.68**# 6.78 ± 1.45**##&&@ 10.20 ± 2.07**##&&@@$
M1
8.54 ± 2.24 8.11 ± 2.78 7.55 ± 2.40 8.67 ± 3.70 9.44 ± 2.12 9.58 ± 2.55
1.11 ± 0.27 2.41 ± 0.43* 2.55 ± 0.38* 2.97 ± 0.55* 4.27 ± 1.10**#& 4.68 ± 1.25**#&@
M2 2.72 ± 1.05 2.55 ± 1.17 5.01 ± 1.23* 5.15 ± 1.87* 6.94 ± 2.70*# 11.22 ± 2.77**##&@$
0.29 ± 0.05 0.65 ± 0.10* 1.51 ± 0.42**# 2.25 ± 0.84**# 3.14 ± 0.42**##& 5.87 ± 1.28**##&&@$
The proportions of CD45+ inflammatory cells in all cells were compared. And then the proportions of different subpopulations in CD45+inflammatory cells (upper
sub-row) and all cells (lower sub-row) were compared,respetively. Th helper T cells, CTL cytotoxic T lymphocyte, Mφ monocyte & macrophage, DC dendritic cells,
NK natural killer cells, NKT natural killer T cells, MDSC myeloid derived suppressor cells, M1 M1-polarized tumor associated macrophages, M2 M2-polarized tumor
assocaited macrophages. Compared with Control group, * P < 0.05, ** P < 0.01; Compared with CP (chronic pancreatitis), #P < 0.05, ##P <0.01; Compared with
PanIN-1 group, & P < 0.05,&& P < 0.01; Compared with PanIN-2, @P < 0.05, @@P < 0.01; Compared with PanIN-3, $P < 0.05, $$P < 0.01; ANOVA analysis, SNK-q test
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Fig. 2 Aspirin inhibited pancreatic cancer-induced MDSC and M2 in vitro, however Lipitor promoted pancreatic cancer-induced M2. a The FCM
results indicated that aspirin significantly inhibited pancreatic cancer-induced MDSC, however Lipitor did not obviously affect pancreatic cancer-
induced MDSC. b The representative plots of FCM. c Western blotting of arginase-1 confirmed the results of FCM. d The FCM results indicated
that aspirin significantly inhibited pancreatic cancer-induced M2, on the contrary, Lipitor obviously promoted pancreatic cancer-induced M2.
e The representative plots of FCM. f Western blotting of CD206 onfirmed the results of FCM. Each experiment was performed in triplicats and the
representative one was shown. ANOVA analysis, SNK-q test, *P < 0.05, **P < 0.01
Table 2 The changes of inflammatory cell populations in peripheral blood and tumor tissue after chemotherapy (n = 5, %, Mean ±
SEM)
Population Peripheral blood Tumor tissue
Control Chemotherapy Control Chemotherapy Control Chemotherapy
in inflammatory cells in all cells
Th 12.21 ± 4.35 15.21 ± 3.37 15.26 ± 2.67 7.20 ± 2.00* 6.11 ± 1.07 2.25 ± 1.04*
CTL 9.45 ± 2.75 9.40 ± 2.75 10.53 ± 2.00 5.56 ± 1.57* 3.12 ± 0.73 1.01 ± 0.55*
B cell 25.54 ± 4.51 30.44 ± 5.23 10.70 ± 1.52 19.07 ± 2.56* 3.45 ± 1.01 6.28 ± 1.27*
Granulocyte 43.57 ± 6.72 37.56 ± 4.55 40.12 ± 6.41 38.56 ± 4.43 12.04 ± 3.27 10.44 ± 2.49
Mφ 10.11 ± 3.58 10.12 ± 2.46 16.61 ± 3.11 24.12 ± 4.12* 5.28 ± 0.76 8.14 ± 1.07*
DC 7.27 ± 2.12 16.45 ± 3.26* 8.13 ± 1.64 15.21 ± 2.12* 2.67 ± 1.22 4.77 ± 1.48*
NK 7.60 ± 1.12 6.55 ± 1.01 4.32 ± 1.12 3.31 ± 1.10 1.24 ± 0.52 1.05 ± 0.75
NKT 3.25 ± 0.44 2.27 ± 0.06 2.30 ± 0.24 3.32 ± 0.57 0.88 ± 0.16 0.75 ± 0.42
MDSC 25.22 ± 5.18 15.20 ± 3.10* 28.67 ± 3.32 18.75 ± 2.35* 7.44 ± 1.29 4.55 ± 0.92*
M1 9.67 ± 2.21 8.55 ± 2.01 7.36 ± 2.91 9.11 ± 2.12 2.46 ± 1.25 3.12 ± 1.09
M2 1.91 ± 1.58 5.11 ± 1.54* 10.97 ± 3.30 18.12 ± 3.56* 3.36 ± 0.70 5.98 ± 1.55*
Th helper T cells, CTL cytotoxic T lymphocyte, Mφ monocyte & macrophage, DC dendritic cells, NK natural killer cells, NKT natural killer T cells, MDSC myeloid
derived suppressor cells, M1 M1-polarized tumor associated macrophages M2, M2-polarized tumor assocaited macrophages. Paired Student t-test, *P < 0.05
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The dynamic changs of inflammatory cells in peripheral
blood and tumor tissue after chemotherapy
After chemotehrapy, the total number of CD45+ inflamma-
tory cells in peripheral blood was significantly decreased.
The peripheral blood total number of CD45+ inflammatory
cells in pancreatic cancer bearing mice without chemother-
apy was 14358.76 ± 5656.22/μl, compared to 7449.7 4 ±
3237.46/μl in ones with chemotherapy. Further analysis of
the subpopulations indicated that the percentages of den-
dritic cells (DC) and M2 were elevated and the percentage
of MDSC was decreased in the peripheral blood. In tumor
tissue, after chemotherapy, the propotion of CD45+ inflam-
matory cells in all cells seemed to be decresaed, however
they were not statistically significant ((37.45 ± 6.98)%:
(44.66 ± 7.32)%, P > 0.05). The percentages of Th, CTL and
MDSC in CD45+ inflammatory cells were significantly de-
creased, in contrary,the percentage of B cell, macropahge,
DC and M2 were significantly elevated. Then the propo-
tions of the 11 subpopulations in total cells in tumor tissue
were analyzed as well. The detail was summarized in
Table 2.
The roles of aspirin and Lipitor to regulate MDSC and TAM
The results from FCM indicated that aspirin significantly
inhibited the expansion of MDSC and the M2, however
Lipitor did not significantly affect MDSC, unexpected to
us, it promoted the expansion of M2 signifiantly. Western
blotting was used to detect, the specific effector of MDSC,
arginas-1 (arg-1) and specific marker of M2 (CD206) as
well. The results confirmed the results of FCM (Fig. 2).
Fig. 3 Aspirin augmented the efficacy of gemcitabine in vitro partially by inhibiting MDSC and M2, however Lipitor weakened the efficacy of aspirin
and Lipitor by promoting M2. a The RAW264.7 macrophages and Panc02 cells were co-cultured, and gemcitabine was used for chemotherapy. The
proportions of M2 (F4/80+ CD16/32+ CD206+) in CD45+ cells were detected by FCM. The results indicated that gemcitabine induced M2, aspirin inhibited
M2, however Lipitor promoted gemcitabine-induced M2. b The representative plots of FCM. c The CFSE stained Panc02 cells were observed under
fluorescent microscope (×100), the results indicated the Panc02 cells were sensitive to gemcitabine, aspirin augmented the efficacy of gemcitabine,
however Lipitor weakened the efficacy of aspirin and gemcitabine. d The BMCs (bone marrow cells) and Panc02 cells were co-cultured, and gemcitabine
was used for chemotherapy as well. The proportions of MDSC (CD11b+ Gr-1+) in CD45+ cells were detected by FCM. The results indicated that gemcitabine
inhibited MDSC, aspirin inhibited MDSC as well, but Lipitor did not significantly affect MDSC. e The representative plots of FCM. f The CFSE stained Panc02
cells were observed under fluorescent microscope (×100), the results indicated aspirin augmented the efficacy of gemcitabine, however Lipitor did not
significantly affect the efficacy of aspirin and gemcitabine. Each experiment was performed in triplicats and the representative one was shown. ANOVA
analysis, SNK-q test, *P< 0.05, **P< 0.01
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Fig. 4 (See legend on next page.)
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The effects of aspirin and Lipitor on the efficacy of
gemcitabine in vitro
The CFSE-labeled Panc02 cancer cells were cultured with
BMCs or RAW264.7 cells and then gemcitabine was used
for chemotherapy. FCM was used to detect the MDSC and
M2. Fluorescence microscopy was used to indicate the
density of CFSE-labeled Panc02 cells. After chemotherapy,
the percentage of M2 significantly increased, and aspirin
inhibited the expansion of MDSC and M2, but Lipitor did
not significantly inhibit MDSC, instead it promoted M2.
The density of pancreac cancer cells indicated that Panc02
cells were sensitive to gemcitabine, and aspirin enhanced
the efficacy of gemcitabine, however Lipitor significantly
weakened the efficacy of gemcitabine and aspirin by pro-
moting M2 (Fig. 3).
The effects of aspirin and Lipitor on the efficacy of
gemcitabine in vivo
Subtaneous implantation of Panc02 cells wer used to test
the efficacy of gemcitabine and the roles of aspirin and Lipi-
tor in vivo. The tumor growth curve indicated that the
similar results like the in vitro results, that is, aspirin had
synergic roles with gemcitabine, however Lipitor attenuated
the efficacy of gemcitabine and aspirin (Fig. 4). The inflam-
matory cell populations in tumor tissue and peripheral
blood of the different groups were analyzed. In peripheral
blood, aspirin had synergic roles to inhibit MDSC with
gemcitabine and as well it inhibited gemcitabine- promoted
M2, however Lipitor significantly enhanced the roles of
gemcitabine to promote M2 (Table 3, Fig. 5). In tumor tis-
sue, gemcitabine induced accumulation of B cells,DC and
M2, on the contrary, it reduced the infiltrations of Th, CTL
and MDSC. Aspirin had synergic roles with gemcitabine to
reduce MDSC, and it also weakened gemcitabine-induced
M2, however Lipitor augmented gemcitabine-induced M2
(Table 4, Fig. 5). Later we anaylzed the cytokines in spleen
and tumor tissue by real time RT-PCR and elisa tests. We
also confirmed that the arginase-1 in spleen and tumor tis-
sue were reduced by gemcitabine and aspirin. Gemcitabine
induced significant systematic and local intratumoral Th2
cytokine environment which could be the curcial factors to
promote M2, aspirin inhibited theses effects of gemcitabien,
however Lipitor augmetned these effects of gemcitabine
(Fig. 6).
The efffects of aspirin and Lipitor on preventing
pancreatic cancerogensis
One hundred sixty mice were used to establish the
model of pancreatic cancerogenesis. Two months later,
the mice were sacrified. Among the four grups, the inci-
dence of pancreatic cancer in the ASP group was the




Control Chemo. Chemo. + ASP Chemo. + Lip Chemo. + ASP + LIP
Th 13.46 ± 3.33 12.01 ± 3.48 13.12 ± 2.16 12.98 ± 2.01 12.01 ± 1.30
CTL 10.44 ± 2.65 9.22 ± 2.65 8.11 ± 2.05 10.11 ± 3.44 9.40 ± 1.75
B cells 27.52 ± 5.01 26.04 ± 5.12 31.01 ± 5.01 22.24 ± 4.01 24.88 ± 6.27
Granulocyte 45.55 ± 7.71 32.33 ± 5.75 32.55 ± 4.66 35.46 ± 4.44 38.22 ± 4.77
Mφ 13.12 ± 3.44 17.11 ± 2.52 9.11 ± 2.05 13.11 ± 4.08 14.01 ± 3.58
DC 7.34 ± 2.06 15.42 ± 2.34* 17.77 ± 4.37* 15.88 ± 1.34* 18.24 ± 2.07*
NK 6.56 ± 2.18 7.50 ± 2.04 5.44 ± 1.25 6.80 ± 1.22 7.70 ± 1.22
NKT 2.29 ± 1.40 3.01 ± 1.26 3.01 ± 0.67 3.20 ± 0.67 3.80 ± 1.04
MDSC 23.21 ± 4.29 14.70 ± 3.14* 7.20 ± 2.45**# 16.01 ± 3.24*& 9.28 ± 1.24**#
M1 7.87 ± 2.88 10.85 ± 1.45 8.58 ± 3.44 9.05 ± 2.75 11.57 ± 2.76
M2 2.91 ± 1.58 7.11 ± 1.54* 3.01 ± 1.05# 11.01 ± 2.04** # 5.22 ± 1.77
Th helper T cells, CTL cytotoxic T lymphocyte, Mφ monocyte & macrophage, DC dendritic cells, NK natural killer cells, NKT natural killer T cells, MDSC myeloid
derived suppressor cells, M1 M1-polarized tumor associated macrophages, M2 M2-polarized tumor assocaited macrophages. Compared with Control group,
* P < 0.05, ** P < 0.01; Compared with Chemo.group, #P < 0.05, ##P < 0.01; Compared with Chemo. + ASP group, & P < 0.05,&& P < 0.01; ANOVA analysis, SNK-q test
(See figure on previous page.)
Fig. 4 Aspirin augmented the efficacy of gemcitabine in vivo, however Lipitor weakened the efficacy of gemcitabine. a Panc02 pancreatic cancer
cells were subcutanously implanted in the immunocompetent mice and then gemcitabine was intrperitoneally injected for chemotherapy.
(a) The tumor growth curve indicated that aspirin augmented the efficacy of gemcitabine, on the contrary, Lipitor weakened the efficacy of
aspirin and gemcitabine. b The final tumor weight confired the results of the tumor growth curver. c The general figure of fresh tumors were
shown. d H&E staining of the necrosis lesions also confirmed the efficacy of aspirin and gemcitabine (×200). Each experiment was performed in
triplicats and the representative one was shown. . ANOVA analysis, SNK-q test, *P < 0.05, **P < 0.01
Liu et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:33 Page 10 of 16
lowest (12.5 %) compared to the other groups (P < 0.05).
When Lipitor was used with aspirin, the protective roles
of aspirin was weakened (ASP: ASP + LIP, 12.5 %: 25 %,
P < 0.05). The detail was summarized in Table 5.
Discussion
Chemopreventive strategies for pancreatic cancerogen-
esis and to improve the efficacy of gemcitabine are of
great value. Pancreatic cancer is a well known inflamma-
tory malignancy with exclusive intratumoral fibrosis and
abundant infiltration of immune cells. Increasing evi-
dence suggests that inflammations influence tumor de-
velopment and the interactions of inflammatory cells
with chemotherapies are more complicated than that
ever been imagined [15–19]. To address these questions,
we tracked the dynamic changes of pan-inflammatory
cell populations during the course of pancreatic cancero-
genesis in a cancerogen DMBA-induced mouse model of
pancreatic cancerogensis and a subtutanous tumor im-
plantation model. This DMBA-induced pancreatic can-
cerogenesis model induces the same characteristic stages
of neoplasia in the evolution of ductal pancreatic cancer
as observed in humans, and the K-ras mutations occur
progressively in the ladder of cancerogenesis, similar to
human pancreatic cancer [20, 21]. Compared with the
genetically engineered mouse model, this model saves
time, animals and cost and can mimic the whole pancre-
atic cancerogenesis process from PanIN to invasive can-
cer in a shorter time period. We found that disease
progression from normal pancreatic tissue, chronic pan-
creatitits, PanIN to pancreatic cancer was accompanied
by a progressive infiltration of CD45+ inflammatory
cells, in which the percentages of granulocyte and mac-
rophages were in prevalence comprising nearly half of
the inflammatory cells at the inception of pancreatic
cancerogenesis and dramatically increased, on the
Fig. 5 The representative plots of the dynamic changes of inflammatory cells in peripheral blood and tumor tissue after chemotherapy. Left plots
from upper to lower were MDSC, DC and M2 in peripheral blood respectively. Right figures from upper to lower were MDSC, DC, B cells, Th, CTL
and M2 in tumor tissue respectively. Each experiment was performed in triplicats and the representative one was shown
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contrary, the proportions of Th and CTL significantly
decreased. The accumulated granulocytes gradually turn
into an immature immunosuppressive phenotye MDSC,
and the macrophages polarized into a tumor-supporting
phenotype M2. The accumulated MDSC and M2 with
reduction of Th cells and CTL indicated an immunosup-
pressive microenvironment at the beginning of the
pancreatic cancerogenesis. The elevated MDSC in per-
ipheral blood of patients with pancreatic cancer was re-
ported to be positively related with tumor stage and
negatively related with prognosis [22, 23]. In a gene
engineered pancreatic cancerogenesis murine mode, the
MDSC was found to accumulate at the inception of can-
cerogensis [24]. The microenvironment of pancreatic
cancer can activate the STAT3 (signal transducers and
activators of transcription 3) signal pathway in MDSC,
and then the activated MDSC can maintain the pancre-
atic cancer stem cells [25, 26], and this feedback poten-
tially could promote pancreatic cancerogenesis and
affect the efficacy of chemotherapy. Macrophages in
tumor can be induced to be an alternatively activated
M2 phenotype mainly by the Th2 cytokine environment,
which has potential immunosuppressive roles and some
other tumor supporting roles [19]. Higher intratumoral
infiltration of M2 predicted poor prognosis of pancreatic
cancer [27, 28]. M2 can promote epithelial-mesenchymal
transition in pancreatic cancer cells, partially through
TLR4/IL-10 signaling pathway [29]. This murine Panc02
pancreatic cancer was highly sensative to gemcitabine.
After chemotherapy, gemcitabine obviously induced a
Th2 biased cytokine microenvironment characterized by
higher level of interleukin-4 (IL-4), interleukin-10 (IL-
10) and TGF-β, as well the percentages of B cells, den-
dritic cells (DC) and M2 in peripheral blood and tumor
tissue were significantly elevated, on the contrary, the
percentages of intratumoral Th cells and CTL, and that
of MDSC in peripheral blood and tumor tissue were de-
creased as well. Besides tumor cell necrosis, gemcitabine
Table 4 The changes of the inflammatory cell populations in tumor tissue after chemotherapy (n = 6, %, Mean ± SEM)
Population Tumor tissue
Control Chemo. Chemo. + ASP Chemo. + Lip Chemo. + ASP + LIP
Inflammatory cells 45.57 ± 6.55 41.01 ± 6.00 38.50 ± 7.43 35.50 ± 4.77 36.55 ± 6.79
Th 14.24 ± 2.54 8.10 ± 2.55* 8.24 ± 2.22* 7.12 ± 2.44* 7.44 ± 2.45*
6.71 ± 1.33 3.54 ± 1.55* 3.27 ± 1.25* 2.75 ± 0.87* 2.72 ± 1.01*
CTL 9.52 ± 1.05 5.57 ± 1.24* 6.22 ± 1.57* 6.11 ± 1.47* 6.22 ± 2.45*
4.05 ± 0.74 1.95 ± 0.57* 2.32 ± 1.05* 1.87 ± 0.48* 2.01 ± 1.14*
B cell 10.11 ± 2.54 18.27 ± 3.54* 18.71 ± 1.33* 17.70 ± 2.02* 19.07 ± 2.44*
4.01 ± 1.11 7.32 ± 1.76* 6.91 ± 1.05* 6.45 ± 1.02* 7.01 ± 1.27*
Granulocyte 31.13 ± 5.65 26.54 ± 4.32 27.58 ± 4.76 27.79 ± 3.33 25.50 ± 4.50
12.70 ± 2.95 10.11 ± 2.75 9.97 ± 2.64 9.45 ± 1.45 9.57 ± 2.27
Macrophage 17.62 ± 3.26 25.17 ± 3.22* 17.03 ± 2.55# 32.04 ± 4.77**#& 25.88 ± 3.46*&
7.45 ± 1.81 10.25 ± 2.02 6.52 ± 1.57# 13.14 ± 1.68*& 9.69 ± 1.78&
DC 7.17 ± 1.33 14.24 ± 2.32* 17.77 ± 2.34* 16.24 ± 1.66* 15.01 ± 1.68*
3.02 ± 0.56 5.87 ± 1.02* 6.75 ± 1.42* 5.64 ± 0.56* 5.42 ± 0.78*
NK 5.34 ± 1.64 4.32 ± 2.17 4.72 ± 1.02 4.44 ± 1.13 4.41 ± 1.02
1.34 ± 0.43 1.27 ± 0.33 1.12 ± 0.24 1.04 ± 0.35 0.97 ± 0.28
NKT 2.34 ± 1.26 3.35 ± 1.58 2.55 ± 0.88 2.24 ± 0.15 4.02 ± 1.21
0.82 ± 0.45 1.05 ± 0.37 0.96 ± 0.46 0.81 ± 0.17 1.11 ± 0.48
MDSC 19.76 ± 4.31 11.65 ± 3.25* 6.34 ± 1.11**# 11.57 ± 1.89*& 7.50 ± 1.45**#@
9.05 ± 2.37 4.75 ± 1.64* 2.88 ± 0.74**# 4.28 ± 0.58*& 2.70 ± 0.84**#@
M1 9.34 ± 2.76 10.22 ± 2.66 10.23 ± 2.67 10.23 ± 3.12 9.37 ± 2.45
3.72 ± 1.43 4.11 ± 1.23 3.56 ± 1.26 3.45 ± 1.24 3.03 ± 1.05
M2 11.98 ± 3.26 18.22 ± 3.37* 15.60 ± 4.34*# 27.89 ± 4.58**#&& 22.11 ± 2.76*&
4.46 ± 1.57 7.68 ± 1.85* 5.81 ± 2.08 10.79 ± 1.75**#& 7.78 ± 1.64*
The proportions of CD45+ inflammatory cells in all cells were compared. And then the proportions of different subpopulations in CD45+inflammatory cells (upper
sub-row) and in all cells (lower sub-row) were compared. Th helper T cells, CTL cytotoxic T lymphocyte, DC dendritic cells, NK natural killer cells, NKT natural killer T
cells, MDSC myeloid derived suppressor cells, M1 M1-polarized tumor associated macrophages, M2 M2-polarized tumor assocaited macrophages. Compared with
Control group, * P < 0.05, ** P < 0.01; Compared with Chemo.group, #P < 0.05, ##P <0.01; Compared with Chemo. + ASP group, & P < 0.05,&& P < 0.01; Compared
with Chemo. + LIP, @P < 0.05, @@P < 0.01; ANOVA analysis, SNK-q test
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also could induce immunogenic death of pancreatic cancer
cells [30], the gemcitabine-induced release of immunogenic
particles of pancreatic cancer cells could be the trigger for
the accumulation of dendritic cells. The lysate pancreatic
cancer stem cells and vaccine-senetised dendritic cells have
obvious synergic roles with gemcitabine [31]. Gemcitabine
can directy inhibit the expansion of MDSC in murine
breast cancer models [32] and in this study, we also found
gemcitabine inhibited expansion of MDSC in bothe tumor
tissue and peripheral blood. We also found after chemo-
therapy, there were more intratumoral B cells. The B cells
impaired the efficacy of platinum and taxol to squamous
cancer by altering chemokine experssion of macrophages
that foster infiltration of activated CD8+ T cells via CCR5-
dependent mechanisms [33]. Th2 cytokine-induced IgG4
positive B cells can dampen the activity of macrophages by
competitively binding to Fc receptor [34], however when
activated by CD40 signal pathway, macrophages can signifi-
cantly improve the efficacy of gemcitabine [35]. Gemcita-
bine dramatically induced M2 expansion in this study. M2
can mediate gemcitabine resistance of pancreatic
Fig. 6 Gemcitabine induced systemic and intratumoral Th2 biased cytokine environment, aspirin weakened these effects of gemcitabine,
however Lipitor augmented these effects. a. The cytokines in spleen were measured by real time RT-PCR. The results indicated that gemcitabine
reduced the levels of IL-6, TNF-α and IL-2, however it increaed the levels of IL-4. Lipitor increased the levels of IL-4 and TGF-β. Aspirin lowered
down IL-6. And the results were confirmed by the elisa tests (d). b. The cytokines in tumor tissues were measured by real time RT-PCR. The results
indicated that gemcitabine reduced the intratumoral levels of IL-6, INF-γ, TNF-α and IL-2, however it elevated the levels of IL-4, IL-10 and TGF-β.
Lipitor increased the levels of IL-4, IL-10 and TGF-β. Aspirin lowered down IL-4, IL-10, TGF-β and IL-6. And the results were confirmed by the elisa
tests (e). c. The arginase in spleens and tumor tissues were detected by real time RT-PCR. The results confirmed the results of FCM, that is, gemcitabine
inhibited MDSC, aspirin inhibited MDSC as well, however Lipitor did not affect MDSC significantly. Each experiment was performed in triplicats and the
representative one was shown. . ANOVA analysis, SNK-q test, *P < 0.05, **P < 0.01
Table 5 The distribution of the pancreatic lesions induced by
DMBA
PanIN
n Death CP I II III CA
Control 40 5 3 6 7 8 11
ASP 40 3 11 10 8 3 5*
LIP 40 5 3 4 7 7 14
ASP + LIP 40 4 5 8 5 8 10
Fisher extact test,*P < 0.05
Liu et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:33 Page 13 of 16
adenocarcinoma by upregulating cytidine deaminase.
Higher level of M2 predicted a poor prognosis of pancre-
atic cancer after chemotherapy [36, 37]. So the accumu-
lated intratumoral B cells induced by gemcitabine could
possibly contribute to secendary drug resistance. After
thoroughly scanning of the dynamic changes of inflamma-
tory cells, we found MDSC and M2 were potential targets
of great values for pancreatic cancer prevention and
imrpoving chemotherapeutic efficacy of gemcitabine.
Aspirin and atorvastatin are always prescribed together
to treat or prevent cardio-cerebral vascular diseases
maily by regulation of inflammations, and they have
been reported to have plausible anti-tumor roles. We
initially attempted to develop novel strategies for pan-
creatic cancer prevention and for improving the efficacy
of gemcitabine by means of combining of these two
drugs partially by regulation of cancer related inflamma-
tions. The COX/PGE axis has been reported to play im-
portant roles to induce MDSC and M2, as an effective
inhibitor of this axis, aspirn has been reported to inhibit
the expansion of MDSC [8], and in this study we also
found aspirin substantially inhibited the expansion of
MDSC and M2 polarization in pancreatic cancer. Lipitor
has been reporetd to inhibit the activation of macro-
phages in several ways. Lipitor suppresses inflammatory
response induced by oxLDL through inhibition of ERK
phosphorylation expression in murine macrophages [10].
Lipitor could induce LPS-mediated MMP experssion by
inhibiting geranylgeranyl pyrophosphate and regulating
phosphorylation of ERK and CREB, and MMP-9 is a
marker for M2 [38]. It can also attenuates TNF-α pro-
duction via Heme Oxygenase-1 Pathway in LPS-
stimulated RAW264.7 macrophages,and TNF-α is a
marker of M1 [39]. In this study, Lipitor significantly
promoted the expansion of M2 in pancreatic cancer. Re-
cently, a study reporetd that Lipitor promoted human
monocyte differentiation toward alternative M2 macro-
phages via p38 MAPK-dependent PPARγ activation in
vitro,envn if, in that study, the M2 was not induced by
pancreatic cancer, it could be also a strong support to
our findings in this paper [40]. When tested for their
roles to prevent cancerogenesis and to improve the effi-
cacy of gemcitabine, aspirin had substantial positive
roles to prevent cancerogenesis and improve chemother-
apeutic efficacy partially by inhibiting MDSC and M2,
however Lipitor weakened the efficacy of aspirin and
gemcitabine partially by promoting M2. Three large
population-based studies did not support that Lipitor,
administered at doses used to manage hypercholesterol-
aemia, could reduce the risk of pancreatic cancer as well
[12, 41, 42]. Some studiese have even proposed that Lipi-
tor are potential cancerogens. In a study conducted on
88,125 cases and 362,254 controls, long-term intake of
Lipitor was associated with a significantly increased risk
of development and recurrence of bladder and lung can-
cer [43, 44]. Pastore et al. [45] found that long-term
treatment with aspirin in patients with non-muscle-
invasive bladder cancer might play a role on reducing
the risk of tumor recurrence. In contrast, statins and
combination treatment groups showed increased recur-
rence rates. Several statins, have been found to be car-
cinogenic in rodents in doses that produce blood
concentrations of the drugs similar to those attained in
treating patients [46]. Our results also did not show any
potential benefit of Lipitor to prevent pancreatic cancer
and to improve chemotherapeutic efficacy of gemcita-
bine, unexpected to us, it even attenuated the positive
roles of aspirin and gemcitabine. We suggest that aspirin
alone could be more effective to prevent cancerogenesis
and improve efficacy of gemcitabine.
Conclusions
In conclusion, our present study demonstrates that 1)
MDSC and M2 dramatically accumulate in the process of
pancreatic cancerogenesis, first the time, we found gemci-
tabine could induce M2 which could be potential mechan-
ism for secendary drug-resistance; 2) Aspirin could inhibit
the expansion of MDSC and M2, but Lipitor promote M2;
3) Aspirin has substantial roles to prevent pancreatic
cancerogenesis and improve the efficacy of gemcitabine
partially by inhibiting MDSC and M2, when used in com-
bination, Lipitor attenuates the postive roles of aspirin and
gemcitabine partially by promoting M2.
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